Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR1E | P28566 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR5A | P47898 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | LSS | P48449 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21815500 | 1.00 | BRD4 (0.50) | BRD4SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL29780550 | 0.89 | SLC6A2 (0.54) | BRD4SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL15786484 | 0.89 | SLC6A2 (0.54) | BRD4SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL578267 | 0.88 | QDPR (0.55) | BRD4QDPRHRH3LSSMDM2 | |
| SCHEMBL31222996 | 0.83 | BRD4 (0.43) | BRD4QDPRHRH3LSSMDM2 | |
| SCHEMBL14544198 | 0.82 | RAB9A (0.50) | SLC6A2SLC6A4SLC6A3KCNH2QDPR | |
| SCHEMBL23134213 | 0.81 | LSS (0.60) | SLC6A2SLC6A4SLC6A3KCNH2LSS | |
| SCHEMBL14320804 | 0.81 | SLC18A3 (0.46) | SLC6A2SLC6A4SLC6A3KCNH2QDPR | |
| SCHEMBL13416053 | 0.81 | NPC1 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2QDPR | |
| SCHEMBL8082343 | 0.81 | LSS (0.60) | SLC6A2SLC6A4SLC6A3KCNH2LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-12377080-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3856348-B1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS | INCYTE CORP (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20220378757-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-01 | — | — | US | disclosed |
| WO-2022226667-A1 | SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| CN-110072860-B | Compounds useful as immunomodulators | 百时美施贵宝公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-3986406-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220017521-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-01-20 | — | — | US | disclosed |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| WO-2020257607-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20150038484-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-8889730-B2 | Indole and indazole compounds that activate AMPK | PFIZER INC. (US) | 2014-11-18 | — | — | US | disclosed |
| WO-2014140704-A1 | INDOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013153479-A2 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20130267493-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-7867980-B2 | Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100184746-A1 | LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD | 2010-07-22 | — | — | US | disclosed |
| EP-2166015-A1 | LINCOSAMIDE DERIVATIVE, AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | BRD4 2372/4885SLC6A2 4663/4885SLC6A4 4564/4885 |
| US-12377080-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB2, ERBB3 | BRD4 2049/4885SLC6A2 4688/4885SLC6A4 4067/4885 |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | HTR6, HTR1B, HTR1F | BRD4 564/4885SLC6A2 75/4885SLC6A4 21/4885 |
| US-20220378757-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | BRD4 2049/4885SLC6A2 4688/4885SLC6A4 4067/4885 |
| US-20150038484-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PRKAG1, PRKAG3, PRKAG2 | BRD4 732/4885SLC6A2 3521/4885SLC6A4 2520/4885 |
| US-20130267493-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PRKAG1, PRKAG3, PRKAG2 | BRD4 732/4885SLC6A2 3521/4885SLC6A4 2520/4885 |
| US-20220017521-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | ALK, FGFR1, FGFR2 | BRD4 2372/4885SLC6A2 4663/4885SLC6A4 4564/4885 |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | BRD4 2372/4885SLC6A2 4663/4885SLC6A4 4564/4885 |
| US-20100184746-A1 | LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | SIRT6, LAS1L, MRPS18A | BRD4 412/4885SLC6A2 4144/4885SLC6A4 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.